FDA
-
-
-
-
-
-
-
Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer
-
-
-
-
-
-
-
Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress
-
-
-
322,245 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

